Compare Natera Inc. Common Stock (NTRA) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Williams Companies Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Williams Companies Inc trades at $72.8 (market cap $91.21B). The key difference: Williams Companies Inc is the larger of the two by market cap, and Williams Companies Inc pays a 2.82% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Williams Companies Inc for 58 Days on average.
| NTRA | WMB | |
|---|---|---|
Market Cap | $57.03B | $91.21B |
Volume | 1,131,157 | 6,950,661 |
Sector | Health | Energy |
52-Week High | $425.64 | $79.40 |
52-Week Low | $179.42 | $56.51 |
Typical Hold Time | 0 Days | 58 Days |
Enterprise Value | $56.18B | $121.84B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Williams Companies (WMB) trades at $72.80, down 1.85% on the day, with strong technical momentum indicated by bullish moving averages. The company maintains robust profitability with 25.18% net income margin and 24.02% ROE, supported by $5.9B operating cash flow in 2025. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 and Q2 2026 missed. The stock benefits from positive analyst sentiment with 79% buy ratings and $87.08 consensus price target, representing 20% upside potential.
WMB presents a compelling investment case with strong dividend growth, exposure to rising natural gas demand from AI data centers, and resilient midstream business model. Key risks include energy market volatility, high debt levels at $24.74B long-term debt, and execution challenges in capital-intensive projects. The stock's valuation at 29.71 P/E appears reasonable given growth prospects, but investors should monitor debt management and energy price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
